| 000 | 02981cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032256.0 | ||
| 008 | 190506s2018 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2018.Ah.T | ||
| 100 | 0 | _aAhmed Mohammed Said Lashin | |
| 245 | 1 | 4 |
_aThe treatment outcome and survival of patients with triple negative breast cancer : _bA retrospective study / _cAhmed Mohammed Said Lashin ; Supervised Thoraya Mohammed Abdelhamid , Hala Aziz Shokralla , Eman Naguib Khourshed |
| 246 | 1 | 5 |
_aنتائج العلاج ومدة البقاء لمرضى سرطان الثدي ثلاثي السلبية : _bدراسة استرجاعية |
| 260 |
_aCairo : _bAhmed Mohammed Said Lashin , _c2018 |
||
| 300 |
_a166 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) | ||
| 520 | _aBackground & Aim:Triple negative breast cancers (TNBC) are a heterogeneous group of tumors defined by negative immunohistochemical staining for estrogen receptor (ER) and progesterone receptor (PR) and lack of human epidermal growth factor receptor 2 (Her2) overexpression. It accounts for approximately 15%-20% of breast cancers diagnosed worldwide.The aim of the study is to assess the clincopathological features, treatment outcome,pattern of failure and survival among the patients diagnosed with early stage triple negative breast cancer treated in the adjuvant settings. In addition, assessment the cytokeratin 5/6 basal marker expression among patients with triple negative breast cancer to define the basal like breast cancer group, and its impact on survival outcome. Patients and Methods:This is a retrospective study included one hundred TNBC patients.The study was done on recorded TNBC cases that were diagnosed, treated and followed up at National Cancer Institute (NCI), Cairo University in the period from January 2012 until December 2014. Study patients were classified into basal like and non-basal like groups based on the positivity of basal cytokeratin 5/6 marker in order to study the difference between the two groups. All cases were analyzed as regards the patients{u2019} clinicopathological characteristics, adjuvant treatment modalities used, patients{u2019} disease free survival (DFS) and overall survival (OS). The median follow up of the study was 44.3 months (Range 21.3-57.9 months) | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCairo University (NCI) | |
| 653 | 4 | _aNational Cancer Institute | |
| 653 | 4 | _aTriple negative breast cancer (TNBC) | |
| 700 | 0 |
_aEman Naguib Khourshed , _eSupervisor |
|
| 700 | 0 |
_aHala Aziz Shokralla , _eSupervisor |
|
| 700 | 0 |
_aThoraya Mohammed Abdelhamid , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c71825 _d71825 |
||